Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 9/2016

01-08-2016 | Original Article

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study

Authors: Seung Hyup Hyun, Jae Seon Eo, Jeong Won Lee, Joon Young Choi, Kyung-Han Lee, Sae Jung Na, Il Ki Hong, Jin Kyoung Oh, Yong An Chung, Bong-Il Song, Tae-Sung Kim, Kyung Sik Kim, Dae Hyuk Moon, Mijin Yun

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2016

Login to get access

Abstract

Purpose

We evaluated the prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) in patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A hepatocellular carcinoma (HCC) who had received curative treatment or transarterial chemoembolization (TACE).

Methods

Between 2009 and 2010, 317 patients diagnosed with HCC at seven hospitals were enrolled. Among these, 195 patients underwent curative treatments including resection, liver transplantation, and radiofrequency ablation. TACE was performed in 122 patients. The tumor-to-normal liver standardized uptake value ratio (TLR) of the primary tumor was measured using pretreatment FDG PET/CT. The prognostic significance of TLR and other clinical variables was assessed using Cox regression models. Differences in the overall survival (OS) associated with TLR or other significant clinical factors were examined using the Kaplan-Meier method.

Results

Over a median follow-up period of 46 months, 77 patients died from cancer. In the curative cohort, higher TLR (≥2) was significantly associated with death (hazard ratio [HR] = 2.68; 95 % CI, 1.16–6.15; P = 0.020) in multivariable analysis. Patients with a higher TLR had significantly worse OS than patients with a lower TLR (5-year overall survival, 61 % vs. 79.4 %; P = 0.006). In the TACE cohort, the Model for End-Stage Liver Disease (MELD) score (≥8) was a significant independent prognostic factor for OS (HR = 3.34; 95 % CI, 1.49–7.48; P = 0.003), whereas TLR was not associated with OS. The Kaplan-Meier curves showed significantly poorer OS in patients with higher MELD scores (≥8) than in those with lower MELD scores (5-year survival rate, 33.1 % vs. 79.6 %; P < 0.001).

Conclusions

Pretreatment TLR measured using FDG PET/CT was an independent prognostic factor for OS in patients with BCLC stage 0 or A HCC undergoing curative treatment. In contrast, underlying liver function appeared to be important in predicting the prognosis of patients undergoing TACE.
Appendix
Available only for authorised users
Literature
1.
go back to reference European Association for The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRef European Association for The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRef
2.
go back to reference Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81:1173–8.CrossRefPubMed Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81:1173–8.CrossRefPubMed
3.
go back to reference Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35:2155–66.CrossRefPubMedPubMedCentral Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35:2155–66.CrossRefPubMedPubMedCentral
4.
go back to reference Eo JS, Paeng JC, Lee DS. Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation. World J Gastroenterol. 2014;20:5375–88.CrossRefPubMedPubMedCentral Eo JS, Paeng JC, Lee DS. Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation. World J Gastroenterol. 2014;20:5375–88.CrossRefPubMedPubMedCentral
5.
go back to reference Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912–21.CrossRefPubMed Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912–21.CrossRefPubMed
6.
go back to reference Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med. 2009;50:682–7.CrossRefPubMed Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med. 2009;50:682–7.CrossRefPubMed
7.
go back to reference Ahn SG, Jeon TJ, Lee SD, Kim SH, Cho HJ, Yun M, et al. A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function. Eur J Surg Oncol. 2013;39:964–73.CrossRefPubMed Ahn SG, Jeon TJ, Lee SD, Kim SH, Cho HJ, Yun M, et al. A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function. Eur J Surg Oncol. 2013;39:964–73.CrossRefPubMed
8.
go back to reference Ahn SG, Kim SH, Jeon TJ, Cho HJ, Choi SB, Yun MJ, et al. The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas. J Gastrointest Surg. 2011;15:2044–52.CrossRefPubMed Ahn SG, Kim SH, Jeon TJ, Cho HJ, Choi SB, Yun MJ, et al. The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas. J Gastrointest Surg. 2011;15:2044–52.CrossRefPubMed
9.
go back to reference Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Yamanaka K, et al. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol. 2012;19:156–62.CrossRefPubMed Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Yamanaka K, et al. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol. 2012;19:156–62.CrossRefPubMed
10.
go back to reference Kornberg A, Freesmeyer M, Barthel E, Jandt K, Katenkamp K, Steenbeck J, et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009;9:592–600.CrossRefPubMed Kornberg A, Freesmeyer M, Barthel E, Jandt K, Katenkamp K, Steenbeck J, et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009;9:592–600.CrossRefPubMed
11.
go back to reference Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427–33.CrossRefPubMed Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427–33.CrossRefPubMed
12.
go back to reference Pant V, Sen IB, Soin AS. Role of 18F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma. Nucl Med Commun. 2013;34:749–57.CrossRefPubMed Pant V, Sen IB, Soin AS. Role of 18F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma. Nucl Med Commun. 2013;34:749–57.CrossRefPubMed
13.
go back to reference Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.CrossRefPubMed Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.CrossRefPubMed
14.
go back to reference Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48:73–85.CrossRef Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48:73–85.CrossRef
15.
go back to reference Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an eastern point of view. Liver Transpl. 2004;10:S3–8.CrossRefPubMed Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an eastern point of view. Liver Transpl. 2004;10:S3–8.CrossRefPubMed
16.
go back to reference Park SK, Jung YK, Chung DH, Kim KK, Park YH, Lee JN, et al. Factors influencing hepatocellular carcinoma prognosis after hepatectomy: a single-center experience. Korean J Intern Med. 2013;28:428–38.CrossRefPubMedPubMedCentral Park SK, Jung YK, Chung DH, Kim KK, Park YH, Lee JN, et al. Factors influencing hepatocellular carcinoma prognosis after hepatectomy: a single-center experience. Korean J Intern Med. 2013;28:428–38.CrossRefPubMedPubMedCentral
17.
go back to reference Ma W, Jia J, Wang S, Bai W, Yi J, Bai M, et al. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics. 2014;4:736–44.CrossRefPubMedPubMedCentral Ma W, Jia J, Wang S, Bai W, Yi J, Bai M, et al. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics. 2014;4:736–44.CrossRefPubMedPubMedCentral
18.
go back to reference Song HJ, Cheng JY, Hu SL, Zhang GY, Fu Y, Zhang YJ. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol. 2015;70:128–37.CrossRefPubMed Song HJ, Cheng JY, Hu SL, Zhang GY, Fu Y, Zhang YJ. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol. 2015;70:128–37.CrossRefPubMed
19.
go back to reference Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, et al. Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging. 2012;46:102–10.CrossRefPubMedPubMedCentral Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, et al. Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging. 2012;46:102–10.CrossRefPubMedPubMedCentral
20.
go back to reference Song MJ, Bae SH, Lee SW, Song d S, Kim HY, Yoo lR, et al. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865–73.CrossRefPubMed Song MJ, Bae SH, Lee SW, Song d S, Kim HY, Yoo lR, et al. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865–73.CrossRefPubMed
21.
go back to reference Lee JW, Yun M, Cho A, Han KH, Kim d Y, Lee SM, et al. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med. 2015;29:400–8.CrossRefPubMed Lee JW, Yun M, Cho A, Han KH, Kim d Y, Lee SM, et al. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med. 2015;29:400–8.CrossRefPubMed
22.
go back to reference Lin WY, Tsai SC, Hung GU. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun. 2005;26:315–21.CrossRefPubMed Lin WY, Tsai SC, Hung GU. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun. 2005;26:315–21.CrossRefPubMed
Metadata
Title
Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study
Authors
Seung Hyup Hyun
Jae Seon Eo
Jeong Won Lee
Joon Young Choi
Kyung-Han Lee
Sae Jung Na
Il Ki Hong
Jin Kyoung Oh
Yong An Chung
Bong-Il Song
Tae-Sung Kim
Kyung Sik Kim
Dae Hyuk Moon
Mijin Yun
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3348-y

Other articles of this Issue 9/2016

European Journal of Nuclear Medicine and Molecular Imaging 9/2016 Go to the issue